依沃布鲁替尼对复发型多发性硬化缓慢扩大病灶体积的影响:一项2期试验的事后分析
本事后分析基于48周双盲随机2期试验(NCT02975349),评估依沃布鲁替尼对复发型多发性硬化患者缓慢扩大病灶(SEL)体积的影响。SEL体积随依沃布鲁替尼剂量增加而下降,75 mg每日两次组较安慰剂/依沃布鲁替尼25 mg每日一次组显著降低,但与富马酸二甲酯组无差异。
要点
- 依沃布鲁替尼75 mg每日两次组SEL体积较安慰剂/依沃布鲁替尼25 mg每日一次组显著降低。
- 依沃布鲁替尼75 mg每日两次组SEL体积较富马酸二甲酯组显著降低。
- 依沃布鲁替尼对SEL体积的影响呈剂量依赖性。
核心结论
- 依沃布鲁替尼以剂量依赖方式降低复发型多发性硬化患者的SEL体积,75 mg每日两次组降低显著。
- 依沃布鲁替尼影响与慢性炎症和组织丢失相关的脑病灶。
研究设计与样本
- 48周双盲随机2期试验(NCT02975349)的事后分析,纳入223例复发型多发性硬化患者。
- 患者接受依沃布鲁替尼25 mg每日一次、75 mg每日一次、75 mg每日两次、安慰剂(第24周后转为依沃布鲁替尼25 mg每日一次)或开放标签富马酸二甲酯240 mg每日两次。
- SEL定义为原有T2病灶随时间缓慢且持续径向扩大的区域,需≥10个连续体素(约30 mm3)。
- SEL通过MRI识别,并用从基线至第48周非线性变形的雅可比行列式评估。
- SEL体积分析按基线T2病灶体积三分位分层,基于第48周/治疗结束状态(完成者/未完成者)。
主要发现
- SEL分析集包括223例患者,平均(SD)年龄42.4(10.7)岁,女性占69.3%,复发缓解型多发性硬化占87.4%。
- 依沃布鲁替尼75 mg每日两次组平均(SD)SEL体积为2,099(2,981.0)mm3,安慰剂/依沃布鲁替尼25 mg每日一次组为2,681(3,624.2)mm3。
- 每例患者SEL中位数在各治疗组间范围为7至11。
关键数值与推荐
- SEL定义为原有T2病灶随时间缓慢且持续径向扩大的区域,需≥10个连续体素(约30 mm3)。
- SEL体积通过从基线至第48周非线性变形的雅可比行列式评估。
- 治疗效应采用分层Hodges-Lehmann分布位移估计和分层Wilcoxon秩和检验分析。
- 亚组分析使用合并治疗组:依沃布鲁替尼高剂量(75 mg每日一次/每日两次)对比低剂量(安慰剂/依沃布鲁替尼25 mg每日一次)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Chronic active lesions (CALs) are demyelinated multiple sclerosis (MS) lesions with ongoing microglia/macrophage activity, resulting in irreversible neuronal damage and axonal loss. Evobrutinib is a highly selective, covalent, CNS-penetrant, Bruton tyrosine kinase inhibitor. This post hoc analysis evaluated the effect of evobrutinib on slowly expanding lesion (SEL) volume, an MRI marker of CALs, assessed baseline-week 48 in a phase 2, double-blind, randomized trial (NCT02975349) in relapsing MS (RMS). METHODS: In the 48-week, double-blind trial, adult patients received evobrutinib (25 mg once daily [QD], 75 mg QD, or 75 mg twice daily [BID]), placebo (switched to evobrutinib 25 mg QD after week 24), or open-label dimethyl fumarate (DMF) 240 mg BID. SELs were defined as slowly and consistently radially expanding areas of preexisting T2 lesions of ≥10 contiguous voxels (∼30 mm3) over time. SELs were identified by MRI and assessed by the Jacobian determinant of the nonlinear deformation from baseline to week 48. SEL volume analysis, stratified by baseline T2 lesion volume tertiles, was based on week 48/end-of-treatment status (completers/non-completers). Treatment effect was analyzed using the stratified Hodges-Lehmann estimate of shift in distribution and stratified Wilcoxon rank-sum test. Comparisons of evobrutinib and DMF vs placebo/evobrutinib 25 mg QD were made. Subgroup analyses used pooled treatment groups (evobrutinib high dose [75 mg QD/BID] vs low dose [placebo/evobrutinib 25 mg QD]). RESULTS: The SEL analysis set included 223 patients (mean [SD] age: 42.4 [10.7] years; 69.3% female; 87.4% relapsing/remitting MS). Mean (SD) SEL volume was 2,099 (2,981.0) mm3 with evobrutinib 75 mg BID vs 2,681 (3,624.2) mm3 with placebo/evobrutinib 25 mg QD. Median number of SELs/patient ranged from 7 to 11 across treatments. SEL volume decreased with increasing evobrutinib dose vs placebo/evobrutinib 25 mg QD, and no difference with DMF vs placebo/evobrutinib 25 mg QD was noted. SEL volume significantly decreased with evobrutinib 75 mg BID vs placebo/evobrutinib 25 mg QD (-474.5 mm3 [-1,098.0 to -3.0], p = 0.047) and vs DMF (-711.6 [-1,290.0 to -149.0], p = 0.011). SEL volume was significantly reduced for evobrutinib high vs low dose within baseline Expanded Disability Status Scale ≥3.5 and longer disease duration (≥8.5 years) subgroups. DISCUSSION: Evobrutinib reduced SEL volume in a dose-dependent manner in RMS, with a significant reduction with evobrutinib 75 mg BID. This is evident that evobrutinib affects brain lesions associated with chronic inflammation and tissue loss. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov number: NCT02975349. Submitted to ClinicalTrials.gov on November 29, 2016. First patient enrolled: March 7, 2017. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that evobrutinib reduces the volume of SELs assessed on MRI comparing baseline with week 48, in patients with RMS.
引用
- Arnold DL, Elliott C, Martin EC, et al. Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial. Neurology. 2024. PMID: 38335474. doi:10.1212/WNL.0000000000208058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。